15,807 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Acquired by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP purchased a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 15,807 shares of the medical research company's stock, valued at approximately $5,193,000. ExodusPoint Capital Management LP owned approximately 0.06% of Bio-Rad Laboratories at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BIO. Metis Global Partners LLC raised its stake in shares of Bio-Rad Laboratories by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock valued at $234,000 after acquiring an additional 30 shares during the period. Signaturefd LLC grew its holdings in Bio-Rad Laboratories by 13.2% during the 4th quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock valued at $87,000 after purchasing an additional 31 shares during the last quarter. UMB Bank n.a. raised its position in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after purchasing an additional 32 shares during the period. Thrivent Financial for Lutherans lifted its stake in Bio-Rad Laboratories by 0.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock worth $1,488,000 after purchasing an additional 32 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its stake in Bio-Rad Laboratories by 3.9% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock worth $296,000 after purchasing an additional 34 shares during the last quarter. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Trading Up 5.7 %

Shares of NYSE BIO traded up $13.14 during trading hours on Friday, reaching $245.43. The stock had a trading volume of 362,886 shares, compared to its average volume of 319,448. Bio-Rad Laboratories, Inc. has a 52-week low of $215.38 and a 52-week high of $387.99. The firm has a market cap of $6.87 billion, a price-to-earnings ratio of -3.77 and a beta of 1.12. The business's fifty day moving average price is $264.86 and its two-hundred day moving average price is $314.80. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BIO has been the topic of a number of analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Wells Fargo & Company cut their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Finally, StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.